Yükleniyor... / Loading...
This study tests the safety and effectiveness of SU011248 (Sunitinib) in patients with non-small cell lung cancer that has spread to the brain (brain metastases). Patients who had previously received whole brain radiation and whose lung cancer had spread to the brain were able to take part. Sponsored by Pfizer, the study was conducted in Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Patients with radiologically proven brain metastases secondary to non-small cell lung cancer * Received previous whole brain radiation therapy and none, 1 or 2 prior systemic therapy for the treatment of advanced/metastatic non-small cell lung cancer Exclusion Criteria: * Patients with brainstem lesions, spinal cord compression. carcinomatous meningitis, or leptomeningeal disease. * Brain metastases \>4 cm in any linear direction * Intracranial or intratumoral hemorrhage